A5114088611- HER2/EGFR in Cancer Research
- Glioma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
- Angiogenesis and VEGF in Cancer
- Cell Adhesion Molecules Research
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer Research and Treatments
- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- RNA Research and Splicing
- Meningioma and schwannoma management
- RNA modifications and cancer
- RNA Interference and Gene Delivery
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Synthesis of Tetrazole Derivatives
- Cancer-related Molecular Pathways
- Mosquito-borne diseases and control
- PI3K/AKT/mTOR signaling in cancer
- Hedgehog Signaling Pathway Studies
Kaiser Permanente Redwood City Medical Center
2009-2025
University of California, Santa Cruz
2023-2025
Canada's Michael Smith Genome Sciences Centre
2024
University of North Carolina at Chapel Hill
2024
Saint Louis University
2023-2024
Stanford University
2007-2018
Stanford Cancer Institute
2018
Northwestern University
2018
University of Hong Kong
2012
Institute for Stem Cell Biology and Regenerative Medicine
2010
Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard newly diagnosed glioblastoma.After surgery chemoradiotherapy, patients were randomized (2:1) receive temozolomide plus DCVax-L (n = 232) or placebo 99). Following recurrence, all allowed DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); secondary...
The success of tissue engineering applications can potentially be dramatically improved with the addition adjuncts that increase proliferation and differentiation progenitor or stem cells. Platelet-rich plasma (PRP) has recently emerged as a potential biologic tool to treat acute chronic tendon disorders. regenerative PRP is based on release growth factors occurs platelet rupture. Its autologous nature gives it significant advantage in applications. To test whether may useful specifically...
Activation of TLR9 by direct injection unmethylated CpG nucleotides into a tumor can induce therapeutic immune response; however, Tregs eventually inhibit the antitumor response and thereby limit power cancer immunotherapies. In tumor-bearing mice, we found that within preferentially express cell surface markers CTLA-4 OX40. We show intratumoral coinjection anti–CTLA-4 anti-OX40 together with depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed low doses...
Activation of TLR9 by direct injection unmethylated CpG nucleotides into a tumor can induce therapeutic immune response; however, Tregs eventually inhibit the antitumor response and thereby limit power cancer immunotherapies. In tumor-bearing mice, we found that within preferentially express cell surface markers CTLA-4 OX40. We show intratumoral coinjection anti-CTLA-4 anti-OX40 together with depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed low doses...
Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.This phase 3, prospective, externally controlled nonrandomized trial compared overall (OS) in newly diagnosed (nGBM) recurrent (rGBM) treated DCVax-L plus SOC vs contemporaneous matched external...
Abstract Purpose: Abegrin is a monoclonal antibody to human integrin αVβ3, cell adhesion molecule highly expressed on actively angiogenic endothelium and glioblastoma multiforme tumor cells. The purpose of this study was evaluate the efficacy novel 90Y-Abegrin radioimmunotherapeutic agent in murine xenograft models with noninvasive vivo molecular imaging modalities. Experimental Design: A s.c. U87MG model used determine maximum tolerated dose (MTD), biodistribution, response, 90Y-Abegrin....
OBJECTIVE: Neoangiogenesis is a prerequisite for the full phenotypic expression and growth of malignant tumor mass. It believed to be triggered by tissue hypoxia involves proliferation sprouting preexisting vessels recruitment endothelial progenitor cells from bone marrow. METHODS: A chimeric mouse model was used examine contribution these neovasculature brain tumor. T-cell knockout (RAG/KO5.2) mice were irradiated lethally, their marrow repopulated with depleted green fluorescent protein...
<p>Supplementary Fig. S9: Imaging mass cytometry. (A) Heatmap of signaling markers expression within cell clusters and (B) Neighbourhood analysis showing cell-to-cell interactions over all patients before after treatment with tomivosertib.</p>
<p>Supplementary Fig. S8: Imaging mass cytometry. (A) Representative images showing marker expression used for our classification. (B) Proportion of immune clusters defined by IMC per patient.</p>
<div>AbstractPurpose:<p>Preclinical data motivate clinical evaluation of inhibitors MAPK-interacting kinases 1 and 2 (MNK1/2). We conducted a phase 1b trial to study target engagement safety tomivosertib, MNK1/2 inhibitor, alone in combination with paclitaxel.</p>Patients Methods:<p>Eligible patients had metastatic breast cancer resistant standard-of-care treatments. Biopsies were obtained at baseline during treatment then tomivosertib was continued the addition...
<p>Supplementary Fig. S6: Translatomic profiling. UpSet plots display overlap of the translationally downregulated (A) and upregulated (B) mRNAs between each patient. The numbers above bars represent number that exclusively belonged to conditions marked below bars. horizontal bar graph on plot's left side shows differentially translated in patient.</p>
<p>Supplementary Fig. S4: Proteomic profiling. Heatmap showing the Normalized Enrichment Score (NES) for main independent pathways enriched in at least 2 of patients cohort.</p>
<p>Supplementary Fig. S5: Translatomic profiling. Scatter plots demonstrating translation efficiency (TE) (top), Ribo-Seq (middle), RNA-Seq) (bottom) the fold change difference between ON MNKi and Pre-MNKi conditions for three different patients, patient 13 (A), 12 (B), 16 (C). Only reads aligning with CDS were considered this analysis. The x-axis represents normalized number of corresponding to experiment/condition minimal expression. Red blue dots denote significantly up or...